类风湿关节炎合并COPD患者中生物制剂与传统合成DMARDs的呼吸道安全性比较
该真实世界队列研究基于美国MarketScan数据库,采用流行新用户设计,将7424例启动生物制剂/靶向合成DMARDs的RA合并COPD患者与7424例匹配的启动传统合成DMARDs患者比较。结果显示,生物制剂/tsDMARDs与csDMARDs相比未增加呼吸道不良事件风险,包括COPD住院加重、支气管炎、肺炎/流感住院及门诊肺炎/流感。
要点
- 生物制剂/tsDMARDs与csDMARDs相比,COPD住院加重风险无显著增加(HR 0.76,95%CI 0.55-1.06)。
- 支气管炎、肺炎/流感住院及门诊肺炎/流感风险在两组间均无显著差异。
- 包括阿巴西普在内的生物制剂/tsDMARDs在RA合并COPD患者中未显示呼吸道安全性信号。
核心结论
- 在RA合并COPD患者中,生物制剂和tsDMARDs(包括阿巴西普)与csDMARDs相比未增加呼吸道不良事件风险。
研究设计与样本
- 基于美国MarketScan数据库的流行新用户设计,纳入7424例启动生物制剂/tsDMARDs的RA合并COPD患者,按时间条件倾向评分匹配7424例启动csDMARDs的患者。
主要发现
- COPD住院加重的调整HR为0.76(95%CI 0.55-1.06)。
- 支气管炎的调整HR为1.02(95%CI 0.82-1.27)。
- 肺炎或流感住院的调整HR为1.21(95%CI 0.92-1.58)。
- 门诊肺炎或流感的调整HR为0.99(95%CI 0.87-1.12)。
- COPD加重、支气管炎和肺炎或流感住院联合终点的HR为1.04(95%CI 0.89-1.21)。
临床怎么用
- 对于RA合并COPD患者,选用生物制剂或tsDMARDs时无需因呼吸道不良事件风险而顾虑,包括阿巴西普。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: Abatacept, a biologic DMARD, was associated with respiratory adverse events in a small subgroup of RA patients with chronic obstructive pulmonary disease (COPD) in a trial. Whether this potential risk is specific to abatacept or extends to all biologics and targeted synthetic DMARDs (tsDMARDs) is unclear. We assessed the risk of adverse respiratory events associated with biologic and tsDMARDs compared with conventional synthetic DMARDs (csDMARDs) among RA patients with concomitant COPD in a large, real-world cohort. METHODS: We used a prevalent new-user design to study RA patients with COPD in the US-based MarketScan databases. New users of biologic DMARDs and/or tsDMARDs were matched on time-conditional propensity scores to new users of csDMARDs. Adverse respiratory events were estimated using Cox models comparing current use of biologic/tsDMARDs with csDMARDs. RESULTS: The cohort included 7424 patients initiating biologic/tsDMARDs and 7424 matched patients initiating csDMARDs. The adjusted hazard ratio of hospitalized COPD exacerbation comparing biologic/tsDMARD vs csDMARD was 0.76 (95% CI: 0.55, 1.06), while it was 1.02 (95% CI: 0.82, 1.27) for bronchitis, 1.21 (95% CI: 0.92, 1.58) for hospitalized pneumonia or influenza and 0.99 (95% CI: 0.87, 1.12) for outpatient pneumonia or influenza. The hazard ratio of the combined end point of COPD exacerbation, bronchitis and hospitalized pneumonia or influenza was 1.04 (95% CI: 0.89, 1.21). CONCLUSION: In this large, real-world comparative safety study, biologic and tsDMARDs, including abatacept, were not associated with an increased risk of adverse respiratory events when compared with csDMARDs in patients with RA and COPD.
引用
- Hudson M, Dell'Aniello S, Shen S, et al. Comparative safety of biologic versus conventional synthetic DMARDs in rheumatoid arthritis with COPD: a real-world population study. Rheumatology (Oxford). 2020. PMID: 31504972. doi:10.1093/rheumatology/kez359
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。